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Abstract
Rationale: Delirium is defined as acute organic brain dysfunction characterised by inattention and disturbance of
cognition. It is common in the intensive care unit and is associated with poorer outcomes. Good quality sleep is
important in the prevention and management of delirium. Melatonin is a natural hormone secreted by the pineal
gland which helps in the regulation of the sleep-wake cycle. It is possible that melatonin supplementation in
intensive care improves sleep and prevents delirium.
Methods and design: The ‘Prophylactic Melatonin for Delirium in Intensive Care’ study is a multi-centre,
randomised, double-blinded, placebo-controlled trial. The primary objective of this study is to determine whether
melatonin given prophylactically decreases delirium in critically ill patients. A total of 850 ICU patients have been
randomised (1:1) to receive either melatonin or a placebo. Participants were monitored twice daily for symptoms of
delirium.
Results: This paper and the attached additional files describe the statistical analysis plan (SAP) for the trial. The SAP
has been developed and submitted for publication before the database has been locked and before the treatment
allocation has been unblinded. The SAP contains details of analyses to be undertaken, which will be reported in the
primary and secondary publications.
Discussion: The SAP details the analyses that will be done to avoid bias coming from knowledge of the results in
advance. This trial will determine whether prophylactic melatonin administered to intensive care unit patients helps
decrease the rate and the severity of delirium.
Trial registration: Australian and New Zealand Clinical Trial Registry (ANZCTR) ACTRN1261600043647, registration
date: 06 April 2016. WHO Trial Number – U1111-1175-1814
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Introduction
Delirium is a condition of acute organic brain dysfunc-
tion with disturbances of attention and cognition, a fluc-
tuating course, and occurring as a direct consequence of
an underlying medical condition [1]. It is particularly
common in patients in intensive care units (ICU), with a
wide range of prevalence reported in the literature (11–
80%) [2–4]. Delirium in ICU is associated with poorer
outcomes, including higher mortality, more time on a
ventilator, increased length of stay (LOS), greater post-
operative complications, increased need for tracheos-
tomy, increased medical costs, and higher risk of
dementia and cognitive impairment [3, 5–12].
Good quality sleep at night is recognised as an import-
ant aspect in the prevention and management of
delirium. Melatonin is a natural hormone secreted by
the pineal gland, which helps in the regulation of the
sleep-wake cycle. Decreased melatonin levels and fluctu-
ations in its metabolite, 6-SMT, have been associated
with delirium in post-surgical and intensive care patients
[13, 14].
It is possible that supplementing melatonin improves
sleep and prevents delirium. A number of clinical trials
of melatonin or melatonin agonists for the prevention of
delirium have been performed to date [15–26]. It is diffi-
cult to draw firm conclusions due to conflicting results,
methodological issues, and patient heterogeneity.
The ‘Prophylactic Melatonin for Delirium in Intensive
Care’ is a multi-centre randomised double-blinded,
placebo-controlled trial. The primary objective of this
study is to determine whether melatonin given prophy-
lactically decreases delirium in critically ill patients.
This study may provide evidence for a simple and
effective agent to reduce delirium in patients admitted
to the ICU.
Study methods
This is a multi-centre, randomised, double-blinded,
placebo-controlled trial of melatonin versus placebo to
decrease the rate of delirium in ICU. A total of 850 ICU
patients have been randomised on a 1:1 ratio to receive
either melatonin or a placebo. Study participants were
administered an oral dose of melatonin 4 mg enterally or
placebo once daily at 21:00hs. for up to 14 days or until
discharge from the ICU. Participants were monitored
twice daily for symptoms of delirium. Additionally, data
is being collected on the duration and severity of delir-
ium, sleep quality, hospital and ICU length of stay
(LOS), duration of mechanical ventilation, and mortality.
Patients were randomised according to a computer-
generated randomisation list, stratified by site, with
standard block sizes of 6. Variable block sizes were con-
sidered unlikely to provide additional benefit, as the
study drug and placebo have the same appearance and
all clinical staff are blinded, thus maintaining allocation
concealment. The randomisation list has been main-
tained by the University of Western Australia Centre for
Applied Statistics.
The patients, investigators, ICU doctors, and nurses
looking after patients enrolled in the study are blinded
to the treatment that the patients are receiving. Only the
University of Western Australia Centre for Applied Sta-
tistics, the compounding pharmacy, and the independent
Data Safety Monitoring Committee (DSMC) (should
they need to, in order to investigate an adverse event)
have had access to the treatment allocation list.
Based on the sample size calculations, with an alpha
value of 0.05 and a power of 80%, a total of 850 patients
have been recruited to the study, with 425 patients in
each arm. Estimates of sample size were made based on
the percentage of delirium-free assessments (the primary
outcome) and, secondarily, the ICU LOS. LOS was
chosen in addition to the percentage of delirium-free as-
sessments as a significant relationship between delirium
and LOS has been observed. Delirium assessment is by
its nature subjective and the investigators wished to also
allow the study to be powered to detect a reduction of
LOS of 1 day (as an objective patient-orientated out-
come). An audit of 100 patients across the two primary
sites was used to provide preliminary data to guide sam-
ple size calculations where an average of 54% of assess-
ments were deemed delirium free (standard deviation of
± 45%). The research group is interested in being able to
detect a 10% increase in the percentage of delirium-free
assessments. This would require a sample size calcula-
tion of 319 per group. Adjustment for non-parametric
data (15%) increases this to 367 per group. It is expected
that up to 10% of patients recruited in the study will not
be assessable for delirium at any point during the study.
To account for this, and missing data/loss to follow-up,
the sample size was increased by 15% to 423 patients per
group (total rounded to 850).
To detect a change in LOS of 1 day, using a sample
size calculation for a gamma distribution, 387 patients
per group would be required. The greater number of
850 was selected to have enough power to answer both
questions. The formula used to calculate sample size
was that described by Wand and Chow in 2007 [27].
The framework of the study is of superiority of
melatonin over placebo for the prevention of delirium.
Superiority analyses will be two-sided and considered
statistically significant at the 5% level.
The DSMC is comprised of an independent intensivist,
an epidemiologist, and a statistician independent of the
trial statistician. The independent DSMC will review all
serious adverse events and perform an interim analysis
after 400 patients using the Haybittle-Peto stopping rule.
The Haybittle-Peto stopping rule states that if an interim
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analysis shows a probability of equal to or less than
0.001 that a difference as extreme or more between the
treatments is found, given that the null hypothesis is
true, then the trial should be stopped early [28].
Statistical analysis of data will all occur collectively
once all data, including follow-up at 90 days, has been
collected. Outcome assessments were undertaken during
ICU stay, at discharge from ICU, at discharge from hos-
pital, and at 28 and 90 days.
Statistical principles
Differences will be considered statistically significant
when P values are < 0.05, and 95% confidence intervals
(95% CI) will be reported.
Adherence to protocol will be considered when pa-
tients have received all the required doses while in ICU
and all the CAM-ICU assessments. This will be pre-
sented with descriptive statistics as a percentage and nu-
merator and denominator. Protocol deviation is defined
as lack of compliance with study drug administration or
lack of assessment with CAM-ICU. All protocol devia-
tions will be collated and presented in the results as de-
scriptive statistics. All analyses will be conducted on
both an intention-to-treat (ITT) and per-protocol (PP)
basis. The ITT sample is defined as all randomised sub-
jects including those who are lost to follow-up or have
missing data. If the patient does not receive the assigned
intervention post-randomisation, the patient will still be
included in the ITT sample and analysed according to
assigned treatment group.
Trial population
Screening data will be presented as descriptive statistics.
Patients eligible to be considered for the study must be
admitted to the ICU with an expected total LOS of at
least 72 h, as determined by the treating intensivist. Eli-
gible participants also must be able to be enrolled and
treated within 48 h of being admitted to the ICU.
Exclusion criteria for participation in the study in-
cludes (1) patients aged < 18 years; (2) patients already
on melatonin before their admission to ICU; (3) prior
hypersensitivity reaction to any of the components of
the study drug (melatonin, sucralose and glycerol,
marshmallow flavour); (4) patients expected to be dis-
charged within 72 h of their ICU admission; (5) ex-
pected/inevitable death within next 48 h; (6) pregnant or
breastfeeding; (7) non-English speaking; (8) patients that
are not expected to improve adequately to be able to be
assessed with a CAM-ICU score during their ICU stay;
(9) patients that are not able to be assessed due to
neurological problems that would affect their ability to
participate in a CAM-ICU assessment, as judged by
treating physician; (10) no enteral route, as melatonin is
not available in intravenous formulation; and (11)
hepatic impairment defined as alanine transferase (ALT)
> 500 IU/L, previous liver transplant, or liver cirrhosis
categories Childs-Pugh B and C.
A CONSORT flow diagram will be presented. (Fig. 1)
This will include the number of patients assessed for
eligibility, excluded, randomised, allocated to each inter-
vention arm, followed up, and analysed for each group.
A report of withdrawals will be provided, describing the
level at which they have occurred, the timing of with-
drawals, and the reasons for the withdrawals.
Baseline characteristics including age, gender, severity
scores, source of admission, and diagnosis will be pre-
sented as a table and summarised.
Analysis
Primary and secondary outcomes will be analysed as de-
scribed below. Where appropriate, analysis of primary
and secondary outcomes will be analysed by a number
of predetermined subgroups. These subgroups will in-
clude (1) percentage of delirium-free assessments by age:
less than 65 or more than 65 years of age; (2) percentage
of delirium-free assessments by gender; (3) percentage of
delirium-free assessments by delirium subgroup at base-
line: hyperactive, hypoactive, and mixed, as well as no
delirium; (4) percentage of delirium-free assessments by
diagnostic category (respiratory, cardiovascular, gastro-
intestinal, toxicological, neurological, metabolic, sepsis,
trauma, traumatic brain injury); and (5) percentage of
delirium-free assessments by > 50% risk or < 50% risk as
per Pre-Deliric Score (calculated from first 24 h of ICU
admission). Multiplicity adjustments will not be made.
For the primary outcome of percentage of delirium-
free episodes, patients will be assessed for delirium twice
a day for 14 days or until they are discharged from ICU,
whichever occurs first. The CAM-ICU tool will be used
to assess delirium, with a result recorded as either ‘posi-
tive’ or ‘negative’ for delirium. The assessment will be
carried out by trained ICU medical or nursing staff. The
percentage of delirium-free assessments will be calcu-
lated for each participant. The percentage of delirium-
free assessments for participants in each group will then
be compared using Student’s t test. It is assumed that
the data will be normally distributed. If the distribution
of the data is not normally distributed, alternative ap-
proaches will be considered; however, the initial plan is
robust to deviations from normality with this sample
size. Supporting analysis will use linear regression mak-
ing adjustments for baseline covariates.
A secondary analysis will look at the rates of delirium
in each group. The number of times an individual is re-
ported as being positive for delirium and the total num-
ber of assessments will be examined by a comparison of
rates. In addition, a Poisson regression will be used with
the number of positive delirium assessments reported
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and offset the total number of assessments. Baseline
characteristics will be included as covariates in the
model. The covariates will include age, gender, delirium
subtype, diagnostic category, and Pre-Deliric score.
Finally, an analysis that looks at whether the individual
reported a positive delirium assessment during their stay
will be undertaken by comparing proportions between
the groups through a logistic regression analysis control-
ling for variables including age, gender and length of
stay.
The secondary outcomes to be analysed include (1)
severity and duration of delirium, (2) sleep quality, (3)
ICU and hospital length of stay;,(4) duration of mech-
anical ventilation, (5) mortality, and (6) economic
analysis. Each secondary outcome will be adjusted for
the same covariates as mentioned before: age, gender,
delirium subtype, diagnostic category, and Pre-Deliric
score.
Severity and duration of delirium
All analyses, with the exception of ‘Delirium and Coma
Free Days’, will use either a linear mixed model ap-
proach or generalised linear mixed model approach.
Both of these will include a random individual effect to
account for the repeated nature of the data and an
appropriate correlation structure. Estimated differences
between the groups and 95% confidence intervals will be
provided throughout. The following analyses will be
undertaken:
Fig. 1 Statistical analysis plan flowchart version 1
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1) CAM-S: Score: CAM-S scores range from 0 (no de-
lirium) to 7 (severe delirium). Linear mixed models
will be used to compare CAM-S score as a response
between the two treatment groups for individuals
who have tested positive using CAM-ICU.
2) Delirium and Coma-Free Days: Poisson regression
will be used to compare the count of delirium and
coma-free days between the treatment groups using
an offset of number of days in ICU.
3) Anti-psychotics or sedation: The use of anti-
psychotics or sedations will be recorded as a binary
outcome labelled ‘used’ or ‘not used’ for each day
during the study period. Generalised linear mixed
models with logit link will be used to compare the
two treatment groups with respect to the binary
outcome.
4) Physical restraint: Each day during the study period,
the use of physical restraints will be recorded as a
binary outcome labelled having been ‘used’ or ‘not
used’. Generalised linear mixed models with logit
link will be used to compare the use of restraints
between the two treatment groups with respect to
the binary outcome.
5) Participation with physiotherapy and mobilisation:
Ability of participate in physiotherapy and
mobilisation sessions will be assessed as a binary
outcome labelled ‘yes’ or ‘no’. Generalised linear
mixed models with logit link will be used to
compare the use of the two treatment groups with
respect to the binary outcome.
6) Patient removal of lines: Each day during the study
period, it will be recorded as whether or not the
patient has attempted to or successfully removed
their lines (binary outcome labelled ‘yes’ or ‘no’).
Generalised linear mixed models with logit link will
be used to compare the used to compare the use of
the two treatment groups with respect to the binary
outcome.
7) Type of delirium: At each assessment, patients with
delirium will be classified as having either
hyperactive, hypoactive, mixed delirium, or no
delirium. Generalised linear mixed models for
ordinal response will be used to compare the use of
the two treatment groups with respect to the
ordinal outcome.
Sleep quality
Sleep quality will be assessed through sleep question-
naires, estimation of hours of sleep, and
polysomnography.
1) Sleep questionnaires: Two types of sleep
questionnaire will be utilised during the study. The
first, the RCSQ provides a score out of 50. The
second (Little’s) involved a mixture of dichotomous
questions and five-point rating questions [29, 30].
2) Estimated hours of sleep: For both questionnaire
responses, calculated outcomes will be compared
between the treatment groups using Student’s t
tests and supporting linear regression models to
adjust for covariates.
3) Polysomnography: In the subset of patients with
polysomnography, the following will be analysed:
total sleep time, sleep efficiency, percentage REM
sleep, arousal index, and odds ratio product.
All calculated outcomes will be compared between the
treatment groups using Student’s t tests and supporting
linear regression models to adjust for covariates.
ICU and hospital length of stay
Initial comparisons between the two groups for ICU and
hospital length of stay will be compared using Student’s
t test. Supporting analysis will also be carried out using
Poisson regression, accounting for previously described
covariates. Length of stay will be analysed in particular
with the aforementioned subgroups.
Duration of mechanical ventilation
The total number of hours of mechanical ventilation will
be calculated for each participant. Comparison between
the two groups will be made using Student’s t test. Sup-
porting analysis will also be carried out using Poisson re-
gression, accounting for covariates such as age, gender,
admission type and diagnosis type.
Mortality
Mortality (time to death) will be analysed using Kaplan-
Meier curves and Cox proportional hazard models, both
unadjusted and adjusting for previously described covar-
iates. Individuals who did not experience an event
(death) will be censored at the end of the follow-up
period of the study. Individuals withdrawn from the
study early or lost to follow-up will be censored at the
date of withdrawal or the last contact visit respectively.
Results will be presented using hazard ratios and 95%
confidence intervals for relative comparisons between
the groups and absolute risk and differences will be esti-
mated at both 28 and 90 days.
Costing analysis
The cost of ICU care has been estimated at $4375 [15]
and $5534 (Medical Division SCGH, 2015) per day based
on national and state data respectively. From these fig-
ures, any reduction in costs through reduced LOS will
be calculated. The cost per melatonin dose ($20 AUD
per 30ml bottle of 2 mg/ml) as well as consumables
(syringe for NGT application) will also be calculated.
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There would also be a small ‘time’ cost associated with
administration, but we believe it could reasonably be in-
cluded in the general nursing workload. Costs will be
presented in Australian dollars, adjusted to 2020.
Missing data
Due to the nature and implementation of the CAM-ICU
tool, it is expected there will be some missing data.
However, such data is expected to be missing at random
and consequently appropriate analyses will be carried
out. The patterns of data availability for primary and
secondary outcomes and reasons for missingness, where
known, will be summarised for the two treatment
groups. In situations where mixed modelling is the pri-
mary analysis, missing data will be handled by the
likelihood-based estimation used in these analyses where
the MAR assumption holds. In other situations of miss-
ing data, analyses will be carried out, if applicable, using
multiple imputation.
It is expected that the source of missing data will be
predominantly the dependent variable (based on missed
delirium free assessments and outcomes). Consequently,
we will not use multiple imputation techniques if this is
the case and simply report the missingness patterns.
However, if missing data is present in other variables, we
will use these techniques, utilising the multiple imput-
ation with chained equations (MICE) methodology [31].
Harms
Safety will be evaluated by tabulation of adverse events
and will be presented with descriptive statistics at base-
line and follow-up visits for each treatment group. With
each SAE, the study investigator will determine the in-
tensity and causality as per ICH GCP guidelines All
SAEs will be discussed at the Data Safety Monitoring
Committee meetings to reach a consensus on causality.
If this differs from the original decision the local ethics
committee is informed.
The number and proportion of patients experiencing
at least one AE, and the number and proportion of pa-
tients experiencing at least one SAE will be presented
descriptively. The mean number of AEs and SAEs per
patient will be presented. In addition, the frequencies of
patients with (i) adverse events and (ii) serious adverse
events will both be compared between the intervention
groups using Fisher’s exact tests or chi-squared tests.
Data analysis will be carried out using the Stata MP,
version 15. This SAP has been written in accordance
with published guidelines for the content of statistical
analysis plans in clinical trials [27].
Trial status
At the time of publication, the ProMEDIC study had
completed enrolment and follow-up of outcome data
was ongoing. The statistical analysis plan of the study
has been submitted for publication to this peer-reviewed
journal before completion of follow-up and unblinding.
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